文献速递免疫规划传染病防控与疫情报告

德国16岁以下儿童侵袭性肺炎球菌疾病:2012/13年PCV13最大效应后发病率反弹不完全

Invasive pneumococcal disease in children under 16 years of age: Incomplete rebound in incidence after the maximum effect of PCV13 in 2012/13 in Germany.
PubMed 文献 · Vaccine · 2017-12-16

该研究通过主动监测和捕获-再捕获校正,分析德国16岁以下儿童侵袭性肺炎球菌疾病(IPD)发病率。最大效应出现在2012/13年(较疫苗接种前下降48%),2015/16年反弹至下降26%。2015/16年非PCV13血清型占84.1%。结论认为需持续监测并可能需要使用所有血清型共同抗原的疫苗。

要点

  • 2009年以来96-97%儿童至少接种两剂肺炎球菌结合疫苗(PCV)。
  • IPD总体发病率最大下降48%出现在2012/13年,2015/16年反弹至下降26%。
  • 2015/16年非PCV13血清型占IPD病例的84.1%。

核心结论

  • 肺炎球菌结合疫苗接种的最大效应已经达到,反弹迹象明显。
  • 需要持续监测儿童IPD以评估这些趋势是否会继续。
  • 可能需要使用所有血清型共同抗原的疫苗。

研究设计与样本

  • 基于两个独立数据源的主动监测,采用捕获-再捕获校正漏报。
  • 报告按年龄组、血清型、感染部位的年发病率和相对发病率下降,并与疫苗接种前时期(1997-2001年)比较。
  • 使用健康保险索赔数据计算24月龄时疫苗接种覆盖率。

主要发现

  • 2009年以来96-97%儿童至少接种两剂PCV。
  • IPD总体发病率最大效应出现在2012/13年,较疫苗接种前下降48%(95%CI:-55%;-39%)。
  • 2015/16年反弹至下降26%(95%CI:-36%;-16%)。
  • 2015/16年非PCV13血清型占IPD病例的84.1%。
  • 2014/15和2015/16年IPD中最常见的非PCV血清型为10A、24F、15C、12F、38、22F、23B和15B。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To identify a potential nadir of the impact of pneumococcal conjugate vaccination (PCV) in infancy on invasive pneumococcal diseases (IPD) in children under 16 in Germany. METHODS: Active surveillance on IPD based on two independent data sources with capture-recapture correction for underreporting. Annual incidence rates by age group, serotypes, site of infection, and relative incidence reduction compared to pre-vaccination period (1997-2001) at nadir and for the most recent season are reported. We calculated vaccine coverage at the age of 24 months using health insurance claims data. RESULTS: 96-97% of children had received at least two doses of PCV since 2009. The maximum impact on overall IPD incidence was achieved in 2012/13 (-48% [95% CI: -55%; -39%]) with a rebound to -26% [95% CI: -36%; -16%] in 2015/16. Non-PCV13 serotypes accounted for 84.1% of the IPD cases in 2015/16. The most frequent non-PCV serotypes in IPD in 2014/15 and 2015/16 were 10A, 24F, 15C, 12F, 38, 22F, 23B, and 15B. The impact at nadir was highest in children 0-1 years of age both in meningitis and non-meningitis cases, whereas the impact for other age groups was higher for meningitis cases. The rebound mainly pertained to non-meningitis cases. CONCLUSION: The maximum impact of pneumococcal conjugate vaccination has been attained and signs of a rebound are apparent. Sustained surveillance for IPD in children is warranted to assess whether these trends will continue. There may be a need for vaccines using antigens common to all serotypes.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Weinberger R, von Kries R, van der Linden M, et al. Invasive pneumococcal disease in children under 16 years of age: Incomplete rebound in incidence after the maximum effect of PCV13 in 2012/13 in Germany. Vaccine. 2017. PMID: 29258705. doi:10.1016/j.vaccine.2017.11.085

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。